Application Note: WB: 0.1-0.3μg/ml. IHC-P: 5-10μg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Calculated MW: 22
Positive Control: The peptide used to generate this antibody is available for purchase (GTX89392-PEP).
Form: Liquid
Buffer (with preservative): TBS, 0.5% BSA, 0.02% Sodium azide.
Concentration: 0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Background: This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]
Uniprot ID: P46527
Antigen Species: Human
Immunogen: Peptide with sequence C-KRPATDDSSTQNK, from the internal region of the protein sequence according to NP_004055.1.
Purification: Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
Conjugation: Unconjugated
Full Name: cyclin dependent kinase inhibitor 1B
Deutsch
English
